NXTC (NextCure, Inc.) is set to announce its Q2'26 results on July 30, time not specified. The earnings are expected to be disclosed at 8:00 AM ET (12:00 PM UTC).For Q2'26, revenue estimate is 0 USD with EPS (earnings per share) anticipated at (1.95) USD. Learn more details at NXTC Financials page…
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We…
NextCure signed a definitive merger agreement with Avere Therapeutics in a stock-for-stock transaction that will result in Avere holders owning about 98% of the combined company, which will be renamed Avere Therapeutics. To support closing, Avere secured a $320 million private placement from instit…
